KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Liabilities and Shareholders Equity: 2009-2025

Historic Liabilities and Shareholders Equity for Neogenomics (NEO) over the last 16 years, with Sep 2025 value amounting to $1.4 billion.

  • Neogenomics' Liabilities and Shareholders Equity fell 16.23% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 billion, marking a year-over-year decrease of 9.05%. This contributed to the annual value of $1.6 billion for FY2024, which is 2.57% down from last year.
  • Neogenomics' Liabilities and Shareholders Equity amounted to $1.4 billion in Q3 2025, which was down 1.38% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Liabilities and Shareholders Equity registered a high of $1.9 billion during Q3 2021, and its lowest value of $1.4 billion during Q3 2025.
  • Over the past 3 years, Neogenomics' median Liabilities and Shareholders Equity value was $1.6 billion (recorded in 2024), while the average stood at $1.6 billion.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first skyrocketed by 6,216.82% in 2021, then declined by 16.23% in 2025.
  • Neogenomics' Liabilities and Shareholders Equity (Quarterly) stood at $1.9 billion in 2021, then declined by 6.94% to $1.7 billion in 2022, then fell by 3.38% to $1.7 billion in 2023, then decreased by 2.57% to $1.6 billion in 2024, then fell by 16.23% to $1.4 billion in 2025.
  • Its last three reported values are $1.4 billion in Q3 2025, $1.4 billion for Q2 2025, and $1.6 billion during Q1 2025.